Updates in Thoracic Oncology
|
|
- Caren Lamb
- 5 years ago
- Views:
Transcription
1 Updates in Thoracic Oncology Dr. Sameena Uddin MD FRCSC Thoracic Surgical Oncologist Division Head, Thoracic Surgery Trillium Health Partners 1
2 Faculty/Presenter Disclosure Faculty: Dr. Sameena Uddin MD, with the Mississauga Halton/Central West Regional Cancer Program: Primary Care Oncology Day Relationship with Commercial Interests: No affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. 2
3 3
4 Updates in Thoracic Oncology Lung Cancer Screening PET CT SBRT Targeted Molecular Therapy 4
5 Updates in Thoracic Oncology - Objectives Overview of Thoracic Oncology Lung Cancer Screening Staging o PET CT o EBUS Treatment o Surgery: VATS, RATS, MIE o Radiation: SBRT o Chemotherapy: Targeted Molecular Therapy 5
6 Thoracic Oncology Lung Cancer Gastroesophageal Cancer Mediastinal Masses Chest Wall Tumours Malignant pleural effusion Pulmonary Metastasis Suspicious Pulmonary Nodules 6
7 The Thoracic Team Medical Oncology Radiation Oncology Respiratory Therapy Respirology Gastroenterology General Surgery Palliative Care Anesthesia Radiology Pathology Nursing Nutrition Psychosocial Physiotherapy CCAC Primary Care 7
8 Mississauga Halton/Central West (MHCW) Regional Cancer Program Mississauga Halton LHIN 6 Central West LHIN 5 LEVEL 1 Regional Thoracic Surgery Program 8
9 LUNG CANCER SCREENING 9
10 Lung Cancer Screening Why? Lung Cancer Statistics Ontario: o Est Incidence = 8,600 o Est Mortality = 6,900 o : 5 year relative survival ratio (age standardized) = 19% o Refer to CCO s Primary Care Referral Guidelines for Suspected Lung 10
11 Lung Cancer Screening How? CXR +/- Sputum cytology o 7 large RCTs have not demonstrated benefit despite up to 20 years of follow-up LOW DOSE SPIRAL CT (LDCT): o Improved sensitivity, technique o 25% less dose than normal CT chest o o 6 Prospective single arm studies o All showed improved sensitivity of LDCT for early stage lung ca o Not well designed or of enough power to show reduction in mortality 11
12 Lung Cancer Screening The Evidence National Lung Screening Trial 2002 o prct August 2002 April 2004 o n= patients at high risk for lung ca o 55-70y, at least 30pk yr hx, if ex-smokers quit within last 15y o 3 annual screenings with LDCT vs control CXR o Primary End-Point: Reduction in Mortality o Secondary End-Points: Rate of death from any cause, and incidence of lung ca in both groups The National Lung Screening Trial Research Team, NEJM
13 Lung Cancer Screening The Evidence Positive screens: 24.2% LDCT vs. 6.9% CXR False Positive: 96.4% LDCT vs. 94.5% CXR Positive = nodule >=4mm Incidence of Lung Cancer o 1060 cancers LDCT vs 941 cancers CXR (rate ratio 1.13) o 20.3% reduction in lung cancer mortality o 7% reduction in all cause mortality The National Lung Screening Trial Research Team, NEJM
14 Incidental Findings = More tests Incidental findings = 19% (Roberts et al. CARJ 2011) o 22% cardiovascular o 78% noncardiovascular (mostly liver and kidney) o Most commonly recommended FU: Abdo US o 10 malignancies: 2 multiple myeloma 1 lymphoma 6 breast cancers 1 thyroid cancer 14
15 Who? What? When? Fleischner Criteria for pulmonary nodules 15
16 Lung Cancer Screening The Problems Lead time Bias: o Early detection before symptomatic phase...no change in time to death...need to be able to change outcome Length Bias: o Slow-growing tumours detected...but aggressive disease not detected or stopped...happened before annual exam Overdiagnosis Bias: o Extra diagnoses of indolent tumours without mortality impact...may have died of unrelated causes without symptoms 16
17 Lung Cancer Screening Questions CT technique Mortality Radiation exposure how long to screen? Impact of screening Screening Demographics Age? Female non-smokers? Follow-up Positive scans? Anxiety Cost! 17
18 CCO Statements CCO s Program in Evidence-Based Care (PEBC) has produced guidelines on the screening of high risk populations for lung cancer: Recommend the use of low-dose computed tomography as a screening modality for lung cancer in high risk populations through an organized screening program and administered by specialized centres with multi-disciplinary care teams CCO has engaged Sunnybrook Research Institute to conduct research to determine the feasibility of an organized lung cancer screening program in Ont Opportunistic screening of asymptomatic individuals is not recommended due to the considerable risks posed to patients outside of an organized program 18
19 PET CT 19
20 20
21 PET CT - Indications o Diagnosis of SPN Biopsy inconclusive Nodule inaccessible to biopsy Medical condition precludes biopsy o Staging of NSCLC o Staging of SCLC o Staging of esophageal cancer Pre-treatment Post-neoadjuvant treatment (chemorads) 21
22 PET CT - Technique Integrated Positron Emission Tomography with CT Functional imaging uses fluorodeoxyglucose (FDG) labelled with radioactive iodine to assess metabolic activity Procedure: o Patient fasting, resting to quiet muscular activity o Given bolus of FDG, then scanned in arms up position o Reconstruction of images completed and SUV values assigned, compared to bloodpool values o Formatted for use by Rad Onc 22
23 PET CT - Diagnosis Diagnosis o Core needle biopsy is recommended as first diagnostic approach o PET reserved for when Bx inconclusive or contraindicated o Sensitivity 96-97% o Specificity 78-66% o False negatives: slow growing malignancies, small <1cm o False positives: inflammatory conditions o No RCT s comparing PET in differentiating benign from malignant SPN 23
24 PET CT - Staging NSCLC, SCLC, Esophageal Cancer o Detects unexpected distant metastases in up to 15% o Eliminates the need for bone scan o For mediastinal lymph nodes there is a 4% false negative rate Invasive mediastinal staging required (EBUS, mediastinoscopy) 24
25 TREATMENT UPDATES: SBRT, TARGETED THERAPY 25
26 Surgery EBUS = Endobronchial Ultrasound VATS = Video assisted thoracoscopic surgery RATS = Robot assisted thoracoscopic surgery MIE = Minimally invasive esophagogastrectomy 26
27 SBRT = Stereotactic Body Radiotherapy SABR = Stereotactic Ablative Radiotherapy Definition: o High doses of radiation via multiple beams o Maximizes radiation dose to tumour o Limited # treatment sessions (high dose/fraction) o Image guided treatment (CT, MRI, PET) o Real time respiratory motion accommodation (4D planning) 27
28 SBRT Anatomic resection remains standard of care for operable, resectable patients with lung cancer But oelderly osevere COPD/Poor PFT s oother medical comorbidities ometastatic disease 28
29 SBRT vs Surgery for Stage 1 NSCLC- Senthi et al. Lancet Oncology 2012 Outcomes o Retrospective analysis of patterns of disease recurrence in early stage NSCLC; n=676 o 5yr Local control 89.5%; Regional control 87.3%, Distant mets 80.1% Grillis et at. JCO 2010: 3yr local control ~90% Onishi et al. JTO 2007: 5yr local control 84.2% Onishi et al. IJROBP 2010: Median F/U 55mon 5y LC = 86.7% (All) 5y OS 69.5% (All) 29
30 Study Pt #/ % IAs/ Med F/U Margins BED (Gy) LC OS DFS Sweden 45 40% IA 43mo 5mm axial 10mm cc % crude 2yr 71% 3yr 55% Amsterdam % IA 12mo ITV + 3mm % crude 2yr 64% 2yr 68% Rotterdam 70 56% IA 5mm yr 96/78% 2yr 62% 2yr 86% 15mo Hi/lo BED Timmerman 70 49% IA 5mm axial 10mm cc yr 88% 3yr 43% 3yr 82% 50mo Japan (no path) % IA Appropriate yr 90% <2cm 14mo 61% >2cm FROG CK 74 88% IA 15mo Custom, histology based yr 93% 2yr 74% 2yr 94% (NS) 30
31 SBRT vs Standard RT Advantages o Higher biologically equivalent dose (BED) o Less collateral damage (lung, cord, heart) o Low incidence of pneumonitis (< 5%) o Virtually no other side effects o Only 3-4 treatment sessions Disadvantages o Need for placement of fiducials o More expensive (but cheaper than surgery??) o Some side effects
32 SBRT - Challenges Heterogeneity of tumours size, location Heterogeneity of patients, comorbidities Selection bias Multiple descriptive endpoints, definitions o Overall survival, LR, LRR, freedom from death or LR Lack of randomized clinical trials o Long and slow process o 2 big RCT s: ROSEL and STARS ROSEL terminated due to poor accrual, STARS struggling 32
33 SBRT vs. Surgery Issues: o Tumour diagnosis? o Stage? Size? o Type of staging? o What risk patient? Surgery o Lobar? Sublobar? Both? o VATS? SBRT o Heterogeneous data o Dose/fractionation? o Central vs. peripheral location? 33
34 SBRT Summary Surgery is the gold standard for operable patients For inoperable, marginally operable patients with Stage 1 NSCLC, SBRT offers 80-90% local control rates, and similar survival to surgical approaches Randomized trials have failed to accrue for various reasons; patients and surgeons 34
35 EGFR and ALK EGFR epidermal growth factor receptor o Somatic mutations o Of tyrosine kinase receptor family o When signalling unregulated, will drive tumour cell proliferation o 15-20% of adenoca will have EGFR mutation ALK anaplastic lymphoma kinase o 2-7% of adenoca *Usually light/never smokers, women, Asian ethnicity (50% vs. 10%)* 37
36 Drugs and Toxicities Tarceva = erlotinib Iressa = gefitinib Gilotrif = afatinib Xalkori = crizotinib Toxicities: MINIMAL o Rash o Diarrhea o (interstitial lung disease) 38
37 Trial Number EGFR M+ Comparison EGFR TKIs in first line therapy Genotype RR PFS directed PFS HR therapy OS (%) (months) (95% CI) (mos) IPASS 261 Gefitinib Carboplatin/paclitaxel ( ) NEJ Gefitinib Carboplatin/paclitaxel ( ) WJTOG Gefitinib Cisplatin/docetaxel ( ) OPTIMAL 165 Erlotinib Carboplatin/gemcitabine ( ) EURTAC 174 Erlotinib Cis-carbo/doce-gem ( ) Fukuoka et al. J Clin Oncol. 2011;29: Inoue et al. Ann Oncol. 2012;Epub ahead of print Mitsudomi et al. ASCO 2012 Zhou et al. ASCO 2012 Rosell et al. Lancet Oncol. 2012;13:239-46
38 Personalized Medicine Role for biomarker assessment o Accurate histology with IHC is mandatory (no NOS) o Routinely test adenoca for EGFR, ALK (do the right test) o Always for Stage IIIB, Stage IV NSCLC Reduced mortality! 40
39 Outcomes Gefitinib vs. Carboplatin/paclitaxel o Mok et al 2009 o Higher response rate (43% vs 32%) o Longer progression free survival with EGFR+ Crizotinib vs standard Chemo o Risk of progression reduced by 50% o Longer progression free survival (7.7 vs 3mos) 41
40 Improved Survival 1.Survival by mutation status. Median survival times: EGFR+, not reached; EGFR -, 3.6 years. p =.001 by log-rank test. Sequist L V et al. The Oncologist 2007;12: Survival by mutation status after adjusting for age, gender, and stage at diagnosis. Median survival times: EGFR+, 3.1 years; EGFR-, 1.6 years. 42
41 Updates in Thoracic Oncology Lung Cancer Screening PET CT SBRT Targeted Molecular Therapy 43
Adam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationSTAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?
STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? MICHAEL LANUTI, MD American Association of Thoracic Surgeons Minneapolis, MN 2013 STAGE I INOPERABLE NSCLC RADIOFREQUENCY
More informationThoracic Recurrences. Soft tissue recurrence
Stereotactic body radiotherapy for thoracic and soft malignancies Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationTherapy of Non-Operable early stage NSCLC
SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationLung Cancer Update. Disclosures. None
Lung Cancer Update Ronald J Servi DO FCCP Adjunct Assistant Professor Department of Pulmonary Medicine University of Texas MD Anderson Cancer Center Banner MD Anderson Cancer Center Gilbert, Arizona Disclosures
More informationTargeted Therapies in the Management of Non-Small Cell Lung Cancer. A Multi-Disciplinary Approach
Targeted Therapies in the Management of Non-Small Cell Lung Cancer A Multi-Disciplinary Approach Course Faculty Medical Oncologists: Dr. Barb Melosky British Columbia Cancer Agency, Vancouver, BC Dr. Jeff
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationLung Cancer Radiotherapy
Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationStereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery
Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation I: Patient ER 74 y/o male with A1A
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationSABR. Outline. Stereotactic Radiosurgery. Stereotactic Radiosurgery. Stereotactic Ablative Radiotherapy
CAGPO Conference October 25, 2014 Outline Stereotactic Radiation for Lung Cancer and Oligometastatic Disease What Every GPO should know Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationLung Cancer Update. HARMESH R NAIK, MD. February 28, 2001
Lung Cancer Update HARMESH R NAIK, MD. February 28, 2001 Progress update Prevention Screening Staging Treatment Epidemiology Estimated 169,500 new cases Estimated 157,400 deaths Second commonest cancer
More informationCritical Clinical Updates
Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,
More informationSurgery versus stereotactic body radiation therapy in medically operable NSCLC
Surgery versus stereotactic body radiation therapy in medically operable NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke
More informationNew Frontiers in Lung Cancer Detection, Diagnosis, and Treatment John Wells, MD MS Shyam Paryani, MD MS MHA First Radiation and
New Frontiers in Lung Cancer Detection, Diagnosis, and Treatment John Wells, MD MS Shyam Paryani, MD MS MHA First Radiation and We have no financially related disclosures However, we do have two other
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationNone
2014 None rosemary clooney Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationThe Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Lung Cancer Screening: Following Up On Abnormal Low Dose CT Scans with
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationLUNG CANCER SCREENING: LUNG CANCER SCREENING: THE TIME HAS COME LUNG CANCER: A NATIONAL EPIDEMIC
: THE TIME HAS COME Physician Leader, Lung Cancer Multi-Disciplinary Program Fletcher Allen Health Care Annual Meeting Montpelier, VT - April 25, 2014 Gerald S. Davis, MD Professor of Medicine University
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationNon-surgical Management of NSCLC
Non-surgical Management of NSCLC Dr. CHAN Siu Hong Oscar MBChB, FRCR(UK), FRCHK, FHKAM PDipID, PDip Epidemiology & Biostatistics Associate Consultant Department of Clinical Oncology Pamela Youde Nethersole
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationLung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationLung Cancer Screening: Benefits and limitations to its Implementation
Lung Cancer Screening: Benefits and limitations to its Implementation Rolando Sanchez, MD Clinical Assistant Professor Pulmonary-Critical Care Medicine University of Iowa Lung cancer - Epidemiology Cancer
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More information- In potentially operable patients -
Lung Stereotactic Ablative Radiotherapy (SABR) - In potentially operable patients - Frank Lagerwaard VUMC Amsterdam Stereotactic Ablative Radiotherapy (SABR) 2003-2008 4DCT-based target definition Non-gated
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationReirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze
Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationLung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationIs the Nodule Malignant? Douglas Arenberg, MD, University of Michigan Health System, Ann Arbor, Michigan
Questions were posed by attendees throughout the meeting using the interactive online question and answer platform. Some questions were addressed during the session, and some of our faculty were able to
More informationDIAGNÓSTICO Y TERAPIAS LOCALES. Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña
DIAGNÓSTICO Y TERAPIAS LOCALES Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña SIDNEY 2013 THE CHALLENGE THE THREE SISTERS: IMAGING, PATHOLOGY AND LOCAL
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationThe Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL
The Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL Conflict of Interest This presentation is supported by AstraZeneca Two main steps before
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationIs Resection Superior to SBRT for Stage I Lesions. Traves Crabtree MD Professor of Surgery Southern Illinois University School of Medicine
Is Resection Superior to SBRT for Stage I Lesions Traves Crabtree MD Professor of Surgery Southern Illinois University School of Medicine I have nothing pertinent to disclose. Patterns of Recurrence for
More informationLung Cancer Case Study
Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but
More informationIntroduction ORIGINAL ARTICLE
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationTHORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationScreening for Lung Cancer: New Guidelines, Old Problems
Screening for Lung Cancer: New Guidelines, Old Problems Robert Schilz DO, PhD Associate Professor of Medicine Interim Chief of the Division of Pulmonary, Critical Care and Sleep Medicine University Hospitals
More information